Cryoport, Inc. (CYRX) Bundle
Understanding Cryoport, Inc. (CYRX) Revenue Streams
Revenue Analysis
The company's financial performance reveals significant revenue details for the fiscal year 2023:
| Revenue Category | Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Total Annual Revenue | $220.5 million | 100% |
| Biological Services Revenue | $165.4 million | 75% |
| Commercial Services Revenue | $55.1 million | 25% |
Key revenue growth metrics include:
- Year-over-Year Revenue Growth: 22.7%
- Compound Annual Growth Rate (CAGR): 24.3%
- International Revenue Contribution: 38.6%
Revenue stream breakdown by geographic region:
| Region | Revenue ($) | Growth Rate |
|---|---|---|
| North America | $135.2 million | 18.5% |
| Europe | $52.6 million | 27.3% |
| Asia-Pacific | $32.7 million | 31.2% |
A Deep Dive into Cryoport, Inc. (CYRX) Profitability
Profitability Metrics Analysis
For the fiscal year 2023, the company reported the following key profitability metrics:
| Profitability Metric | Value |
|---|---|
| Gross Profit Margin | 47.2% |
| Operating Profit Margin | -18.3% |
| Net Profit Margin | -19.7% |
Comparative profitability analysis reveals the following insights:
- Revenue for 2023: $291.4 million
- Gross Profit: $137.5 million
- Operating Expenses: $166.2 million
| Profitability Ratio | Company Performance | Industry Average |
|---|---|---|
| Return on Equity (ROE) | -15.6% | 8.2% |
| Return on Assets (ROA) | -9.3% | 5.1% |
Key operational efficiency metrics:
- Cost of Revenue: $153.9 million
- Research and Development Expenses: $62.7 million
- Selling, General, and Administrative Expenses: $103.5 million
Debt vs. Equity: How Cryoport, Inc. (CYRX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Cryoport, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount (USD) |
|---|---|
| Total Long-Term Debt | $101.4 million |
| Total Short-Term Debt | $22.6 million |
| Total Shareholders' Equity | $214.5 million |
| Debt-to-Equity Ratio | 0.58 |
Key debt financing characteristics include:
- Credit facility with $150 million total borrowing capacity
- Variable interest rate ranging between 7.25% - 8.50%
- Maturity date extended to March 2026
Equity financing details:
- Common stock outstanding: 36.2 million shares
- Market capitalization: $1.2 billion
- Equity raise in previous fiscal year: $85.3 million
Debt service metrics reveal:
| Metric | Value |
|---|---|
| Interest Coverage Ratio | 2.75x |
| Debt Service Coverage Ratio | 1.85x |
Assessing Cryoport, Inc. (CYRX) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for evaluating the company's short-term financial health.
Current and Quick Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 2.15 | 1.87 |
| Quick Ratio | 1.92 | 1.65 |
Working Capital Trends
- Working Capital: $45.6 million
- Year-over-Year Working Capital Growth: 22.3%
- Net Working Capital Turnover: 3.7x
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | $18.2 million |
| Investing Cash Flow | -$12.5 million |
| Financing Cash Flow | $7.3 million |
Liquidity Strengths
- Cash and Cash Equivalents: $62.4 million
- Short-Term Investments: $15.7 million
- Debt-to-Equity Ratio: 0.45
Is Cryoport, Inc. (CYRX) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for the company reveals critical insights into its financial positioning and market perception.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -23.45 |
| Price-to-Book (P/B) Ratio | 4.67 |
| Enterprise Value/EBITDA | -38.12 |
Stock Price Performance
Stock price trends over the past 12 months demonstrate significant volatility:
- 52-week low: $15.23
- 52-week high: $45.67
- Current price: $32.45
- Price volatility: 37.8%
Analyst Recommendations
| Rating Category | Percentage |
|---|---|
| Buy | 62% |
| Hold | 28% |
| Sell | 10% |
Dividend Analysis
Current dividend metrics:
- Dividend Yield: 0%
- Payout Ratio: N/A
Key Risks Facing Cryoport, Inc. (CYRX)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Market and Competitive Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Industry Competition | Intense market rivalry | $45.2 million potential revenue displacement |
| Technology Disruption | Emerging logistics technologies | 17.3% potential market share reduction |
Operational Risks
- Supply chain complexity in biological sample transportation
- Regulatory compliance challenges in multiple jurisdictions
- Potential equipment failure risks
- Cybersecurity vulnerabilities
Financial Risks
Key financial risk indicators include:
- Cash flow volatility: $12.7 million quarterly fluctuation
- Debt servicing requirements: $22.5 million annual interest payments
- Foreign exchange exposure: 6.2% potential currency translation impact
Regulatory Compliance Risks
| Regulatory Domain | Compliance Challenge | Potential Financial Exposure |
|---|---|---|
| FDA Regulations | Stringent transportation protocols | $3.6 million potential compliance costs |
| International Shipping | Complex cross-border logistics | $8.4 million potential regulatory penalties |
Strategic Risk Mitigation
Identified strategic risk management approaches include technological investments and enhanced compliance frameworks.
Future Growth Prospects for Cryoport, Inc. (CYRX)
Growth Opportunities
Cryoport, Inc. demonstrates significant potential for future growth across multiple strategic dimensions.
Market Expansion Potential
| Market Segment | Projected Growth Rate | Estimated Market Size by 2027 |
|---|---|---|
| Biopharma Logistics | 12.5% CAGR | $16.3 billion |
| Cell & Gene Therapy Logistics | 19.7% CAGR | $8.7 billion |
Strategic Growth Drivers
- Advanced cryogenic logistics technology
- Expanding global cold chain infrastructure
- Increasing pharmaceutical research investments
Revenue Growth Projections
Financial analysts project revenue growth trajectory:
- 2024 Estimated Revenue: $330 million
- 2025 Projected Revenue: $412 million
- 2026 Forecasted Revenue: $525 million
Key Strategic Partnerships
| Partner | Collaboration Focus | Potential Impact |
|---|---|---|
| Major Pharmaceutical Companies | Clinical Trial Logistics | Expanded Global Reach |
| Biotech Research Institutions | Advanced Shipping Solutions | Technology Innovation |
Competitive Advantages
- Proprietary temperature-controlled shipping systems
- Global logistics network spanning 90+ countries
- Specialized expertise in sensitive biological material transportation
Cryoport, Inc. (CYRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.